Project List
List projects.
Fields
id (integer)
Primary key.
Expansions
To activate relation expansion add the desired fields as a comma separated
list to the expand query parameter like this:
?expand=<field>,<field>,<field>,...
The following relational fields can be expanded:
organizationcategorytypepartner_functionmanagercontactstatusgrantresearcheventstudylanguageprogramfunders
Filters
To filter for exact value matches:
?<fieldname>=<value>
Possible exact filters:
organizationcategorymanagercontactstatusgrantresearchstudylanguagefundersprogram
For advanced filtering use lookups:
?<fieldname>__<lookup>=<value>
All fields with advanced lookups can also be used for exact value matches as described above.
Possible advanced lookups:
begin_planned:gt,gte,lt,ltebegin_effective:gt,gte,lt,lteend_planned:gt,gte,lt,lteend_effective:gt,gte,lt,lte
GET /v1/research/project/?format=api&offset=180&ordering=begin_planned
{ "count": 2242, "next": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=200&ordering=begin_planned", "previous": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=160&ordering=begin_planned", "results": [ { "id": 1819, "title": { "de": "Nano-Health: 4D Molecular Imaging of human Stem Cells in vivo", "en": "Nano-Health: 4D Molecular Imaging of human Stem Cells in vivo" }, "short": "Nano-Health: 4D Imaging of Stem Cells", "url": null, "abstract": { "de": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity", "en": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity" }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2009-03-01T01:00:00+01:00", "end_planned": "2012-02-28T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-05-18T11:50:29+02:00", "program": null, "subprogram": "Nano-Health", "organization": 14082, "category": 10, "type": 10, "partner_function": 2, "manager": null, "contact": null, "status": 2, "research": 3, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 416 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1819-50747-12" ] }, { "id": 2660, "title": { "de": "Doktoratskolleg \"Metabolische und kardiovaskuläre Erkrankungen\" ", "en": "Doktoratskolleg: \"Metabolic and cardiovascular disease\"" }, "short": "DK_METABOL_DISORDERS", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2010-07-01T02:00:00+02:00", "end_planned": "2012-02-28T01:00:00+01:00", "end_effective": "2014-06-30T02:00:00+02:00", "assignment": "2010-10-20T13:09:58+02:00", "program": 66, "subprogram": null, "organization": 14081, "category": 10, "type": 10, "partner_function": 2, "manager": null, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "W1226", "ethics_committee": null, "edudract_number": null, "persons": [ "2660-66436-12" ] }, { "id": 2659, "title": { "de": "Doktoratskolleg \"Metabolische und kardiovaskuläre Erkrankungen\" ", "en": "Doktoratskolleg: \"Metabolic and cardiovascular disease\"" }, "short": "DK_METABOL_DISORDERS", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2010-07-01T02:00:00+02:00", "end_planned": "2012-02-28T01:00:00+01:00", "end_effective": "2014-06-30T02:00:00+02:00", "assignment": "2010-10-20T13:09:58+02:00", "program": 66, "subprogram": null, "organization": 14021, "category": 10, "type": 10, "partner_function": 2, "manager": null, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "W1226", "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 1820, "title": { "de": "NANO-AS: Nano-Tox-Verlängerung", "en": "NANO-AS: Nano-Tox-Verlängerung" }, "short": "NANO-AS", "url": null, "abstract": { "de": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity", "en": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity" }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2009-03-01T01:00:00+01:00", "end_planned": "2012-02-28T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-05-18T12:36:34+02:00", "program": null, "subprogram": "Nano-Health", "organization": 28394, "category": 10, "type": 10, "partner_function": 2, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 416 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 2663, "title": { "de": "Doktoratskolleg \"Metabolische und Kardiovaskuläre Erkrankungen\"", "en": "Doktoratskolleg: \"Metabolic and cardiovascular disease\"" }, "short": "DK_METABOL_DISORDERS", "url": null, "abstract": { "de": "Projekt 1 erarbeit die subuellulären Mechanismen getriggerter Arrhythmien unter besonderer Berücksichtigung eines gestörten Funktion des Ryanodin-Rezeptors des sarkoplasmatischen Retikulums.\r\n\r\nProjekt 2 untersucht den Einfluss von milder Hypothermie auf Hämodynamik, zelluläre und subzelluläre Funktion im Schockmodell und Sepsismodell.", "en": null }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2010-07-01T02:00:00+02:00", "end_planned": "2012-02-28T01:00:00+01:00", "end_effective": "2014-06-30T02:00:00+02:00", "assignment": "2009-12-18T01:00:00+01:00", "program": 66, "subprogram": null, "organization": 14083, "category": 10, "type": 10, "partner_function": 2, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "W1226", "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 1821, "title": { "de": "Nano-Health: Nano-Plaque-Extension", "en": "Nano-Health: Nano-Plaque-Extension" }, "short": "Nano-Plaque-Extension", "url": null, "abstract": { "de": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity", "en": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity" }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2009-03-01T01:00:00+01:00", "end_planned": "2012-01-28T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-05-18T13:05:25+02:00", "program": null, "subprogram": "Nano-Health Verlängerung", "organization": 14028, "category": 10, "type": 10, "partner_function": 2, "manager": 52854, "contact": 52854, "status": 2, "research": 3, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 416 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1821-52854-10" ] }, { "id": 2661, "title": { "de": "Doktoratskolleg \"Metabolische und Kardiovaskuläre Erkrankungen\"", "en": "Doktoratskolleg: \"Metabolic and cardiovascular disease\"" }, "short": "DK_METABOL_DISORDERS", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2010-07-01T02:00:00+02:00", "end_planned": "2012-02-28T01:00:00+01:00", "end_effective": "2014-06-30T02:00:00+02:00", "assignment": "2010-10-20T13:09:58+02:00", "program": 66, "subprogram": null, "organization": 14020, "category": 10, "type": 10, "partner_function": 2, "manager": 51663, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "W1226", "ethics_committee": null, "edudract_number": null, "persons": [ "2661-51663-10" ] }, { "id": 2657, "title": { "de": "Doktoratskolleg \"Metabolische und kardiovaskuläre Erkrankungen\" ", "en": "Doktoratskolleg: \"Metabolic and cardiovascular disease\"" }, "short": "DK_METABOL_DISORDERS", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2010-07-01T02:00:00+02:00", "end_planned": "2012-02-28T01:00:00+01:00", "end_effective": "2014-10-31T01:00:00+01:00", "assignment": "2010-10-20T13:09:58+02:00", "program": 66, "subprogram": null, "organization": 14013, "category": 10, "type": 10, "partner_function": 2, "manager": 51833, "contact": 51833, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "W1226", "ethics_committee": null, "edudract_number": null, "persons": [ "2657-51833-10" ] }, { "id": 2391, "title": { "de": "Einfluss der Knochenentnahmetechnik auf die Osteoblastenaktivität", "en": "Effect of Bone Harvesting Methods to the Osteoblast activity" }, "short": "KNOCHENENTNAHME_OSTEOBLAST", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-04-01T02:00:00+02:00", "begin_effective": "2011-01-26T01:00:00+01:00", "end_planned": "2010-10-01T02:00:00+02:00", "end_effective": "2017-12-31T01:00:00+01:00", "assignment": "2011-02-04T09:47:14+01:00", "program": null, "subprogram": null, "organization": 14057, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 4, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 2008, "title": { "de": "Ganganalysen bei Kindern mit Morbus Perthes", "en": "Ganganalysen bei Kindern mit Morbus Perthes" }, "short": "Morbus Perthes", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-04-01T02:00:00+02:00", "begin_effective": "2009-04-01T02:00:00+02:00", "end_planned": "2009-08-31T02:00:00+02:00", "end_effective": "2012-07-31T02:00:00+02:00", "assignment": "2009-12-04T11:57:57+01:00", "program": null, "subprogram": "Land Steiermark Abteilung 3", "organization": 14049, "category": 10, "type": 10, "partner_function": 4, "manager": 65038, "contact": 65038, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2008-65038-10" ] }, { "id": 1940, "title": { "de": "Altered prostaglandin receptor function in patients with aspirin intolerance", "en": "Altered prostaglandin receptor function in patients with aspirin intolerance" }, "short": "Prostaglandin receptor function", "url": null, "abstract": { "de": "Prostaglandin E2 (PGE2) limitiert in der Lunge immunologische und entzündliche Prozesse. Eosinophile Granulozyten spielen eine entscheidende Rolle bei der Pathogenese von Asthma bronchiale. Etwa 10% der Asthmapatienten vertragen keine Analgetika vom Typ der nichtsteroidalen Antirheumatika (z.B. Aspirin). Daher ist eine effektive Schmerz- und Entzündungstherapie bei diesen Patienten schwierig. Wir konnten zeigen, dass PGE2 hemmende Effekte an eosinophilen Granulozyten hat. Die Effekte von PGE2 werden durch vier Rezeptoren vermittelt. Wir untersuchen, inwieweit die Wirkungen von PGE2 auf Eosinophile von Patienten mit Aspirin-Unverträglichkeit verändert sind und welche Rolle die PGE2 Rezeptoren spielen. Als Vergleich dienen gesunde Probanden, allergische Patienten ohne Asthma und Asthmatiker ohne Aspirin-Unverträglichkeit. Diese Studie soll das Verständnis der Rolle von PGE2 bei Asthma und Aspirin-Unverträglichkeit erweitern, und möglicherweise neue therapeutische Optionen eröffen.", "en": "Prostaglandin E2 (PGE2) limitiert in der Lunge immunologische und entzündliche Prozesse. Eosinophile Granulozyten spielen eine entscheidende Rolle bei der Pathogenese von Asthma bronchiale. Etwa 10% der Asthmapatienten vertragen keine Analgetika vom Typ der nichtsteroidalen Antirheumatika (z.B. Aspirin). Daher ist eine effektive Schmerz- und Entzündungstherapie bei diesen Patienten schwierig. Wir konnten zeigen, dass PGE2 hemmende Effekte an eosinophilen Granulozyten hat. Die Effekte von PGE2 werden durch vier Rezeptoren vermittelt. Wir untersuchen, inwieweit die Wirkungen von PGE2 auf Eosinophile von Patienten mit Aspirin-Unverträglichkeit verändert sind und welche Rolle die PGE2 Rezeptoren spielen. Als Vergleich dienen gesunde Probanden, allergische Patienten ohne Asthma und Asthmatiker ohne Aspirin-Unverträglichkeit. Diese Studie soll das Verständnis der Rolle von PGE2 bei Asthma und Aspirin-Unverträglichkeit erweitern, und möglicherweise neue therapeutische Optionen eröffen." }, "begin_planned": "2009-04-01T02:00:00+02:00", "begin_effective": "2010-01-01T01:00:00+01:00", "end_planned": "2011-03-31T02:00:00+02:00", "end_effective": "2013-09-30T02:00:00+02:00", "assignment": "2009-10-01T18:22:11+02:00", "program": 79, "subprogram": null, "organization": 14022, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 12 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 1732, "title": { "de": "Zerebrale und peripher-muskuläre Gewebssättigung unmittelbar nach der Geburt [Postpartale zerebrale und periphere Oxygenierung bei reifen Neugeborenen und Frühgeborenen]", "en": "Transition after birth: cerebral and peripheral muscle oxygenation in term and preterm neonates" }, "short": "Oxygenierung", "url": null, "abstract": { "de": "Mit Nah-Infrarot Spektroskopie (NIRS) kann die Oxygenierung in verschiedenen Gewebsregionen gemessen werden. Zahlreiche Studien bei reifen Neugeborenen und Frühgeborenen wurden bereits durchgeführt, wobei es jedoch noch keine Daten der zerebralen und peripher-muskulären Oxygenierung unmittelbar nach der Geburt gibt. \r\nZiel der vorliegenden Studie ist es daher, die zerebrale und peripher-muskuläre Oxygenierung unmittelbar nach der Geburt mit NIRS zu messen und zu analysieren. Sollte eine Atemunterstützung mit Maske notwendig sein, wird der Einfluss von \"continuous positive airway pressure\" (CPAP) oder \"positive pressure ventilation\" (PPV) analysiert. Das Studiendesign ist prospektiv beobachtend.\r\nNIRS wird kombiniert mit nicht-invasivem Monitoring der arteriellen Sauerstoffsättigung, der Herzfrequenz, der Hämoglobinkonzentration, des Blutdrucks, mit einer Videodokumentation und -bei Atemunterstützung mit CPAP oder PPV- mit einem Atemfunktionsmonitoring.", "en": "Mit Nah-Infrarot Spektroskopie (NIRS) kann die Oxygenierung in verschiedenen Gewebsregionen gemessen werden. Zahlreiche Studien bei reifen Neugeborenen und Frühgeborenen wurden bereits durchgeführt, wobei es jedoch noch keine Daten der zerebralen und peripher-muskulären Oxygenierung unmittelbar nach der Geburt gibt. \r\nZiel der vorliegenden Studie ist es daher, die zerebrale und peripher-muskuläre Oxygenierung unmittelbar nach der Geburt mit NIRS zu messen und zu analysieren. Sollte eine Atemunterstützung mit Maske notwendig sein, wird der Einfluss von \"continuous positive airway pressure\" (CPAP) oder \"positive pressure ventilation\" (PPV) analysiert. Das Studiendesign ist prospektiv beobachtend.\r\nNIRS wird kombiniert mit nicht-invasivem Monitoring der arteriellen Sauerstoffsättigung, der Herzfrequenz, der Hämoglobinkonzentration, des Blutdrucks, mit einer Videodokumentation und -bei Atemunterstützung mit CPAP oder PPV- mit einem Atemfunktionsmonitoring." }, "begin_planned": "2009-04-01T02:00:00+02:00", "begin_effective": "2009-04-01T02:00:00+02:00", "end_planned": "2011-03-31T02:00:00+02:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-01-19T12:54:11+01:00", "program": 79, "subprogram": null, "organization": 14094, "category": 10, "type": 10, "partner_function": 4, "manager": 50907, "contact": 50907, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 12 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1732-50907-10" ] }, { "id": 1931, "title": { "de": "Expression der Glykoproteine B7-H1 und B7-H3 auf Tumorzellen von Patienten mit metastasiertem, klarzelligem Nierenzellkarzinom. Einfluss der Glykoproteine auf die Prognose", "en": "Expression der Glykoproteine B7-H1 und B7-H3 auf Tumorzellen von Patienten mit metastasiertem, klarzelligem Nierenzellkarzinom. Einfluss der Glykoproteine auf die Prognose" }, "short": "Expression der Glykoproteine B7-H3", "url": null, "abstract": { "de": "Das metastasierte Nierenzellkarzinom ist ein aggressiver Tumor der weder strahlen- noch chemosensibel ist. Auftretende singuläre Metastasen werden wenn möglich immer chirurgisch entfernt. Bei multipler Metastasierung kommt eine Immuntherapie sowie eine Anti-angiogenetische Therapie oder auch eine Kombination aus beiden zur Anwendung. In den letzten 20 Jahren war die Immuntherapie die einzig erfolgreiche Therapie bei diesen Patienten. In den letzten Jahren wurden eine Reihe von co-inhibitorischen und co-stimulatorischen Molekülen auf Zellen des Immunsystems aber auch auf Tumorzellen gefunden. Diese Moleküle können einzelne Zellen im Immunsystem blockieren oder aber stimulieren.\r\nWir glauben, dass Patienten die die co-inhibitorischen Moleküle B7-H1 und B7-H3 an ihrer Oberfläche exprimieren, eine unterdrückte Immunabwehr haben und, dass diese Patienten aus diesem Grund schlecht auf einen Immuntherapie ansprechen und früher versterben. \r\nUnser Ziel ist es, das Gewebe aller Patienten die wir in den letzten 15 Jahren mit einer Immuntherapie behandelt haben zu färben und zu evaluieren ob sie B7-H1 und B7-H3 exprimieren.\r\nEs wäre von großem Vorteil Patienten von vornherein identifizieren zu können, die auf eine Immuntherapie ansprechen. Dadurch könnte den Patienten die nicht ansprechen von vornherein eine oft recht nebenwirkungsreiche Therapie erspart werden.", "en": "Das metastasierte Nierenzellkarzinom ist ein aggressiver Tumor der weder strahlen- noch chemosensibel ist. Auftretende singuläre Metastasen werden wenn möglich immer chirurgisch entfernt. Bei multipler Metastasierung kommt eine Immuntherapie sowie eine Anti-angiogenetische Therapie oder auch eine Kombination aus beiden zur Anwendung. In den letzten 20 Jahren war die Immuntherapie die einzig erfolgreiche Therapie bei diesen Patienten. In den letzten Jahren wurden eine Reihe von co-inhibitorischen und co-stimulatorischen Molekülen auf Zellen des Immunsystems aber auch auf Tumorzellen gefunden. Diese Moleküle können einzelne Zellen im Immunsystem blockieren oder aber stimulieren.\r\nWir glauben, dass Patienten die die co-inhibitorischen Moleküle B7-H1 und B7-H3 an ihrer Oberfläche exprimieren, eine unterdrückte Immunabwehr haben und, dass diese Patienten aus diesem Grund schlecht auf einen Immuntherapie ansprechen und früher versterben. \r\nUnser Ziel ist es, das Gewebe aller Patienten die wir in den letzten 15 Jahren mit einer Immuntherapie behandelt haben zu färben und zu evaluieren ob sie B7-H1 und B7-H3 exprimieren.\r\nEs wäre von großem Vorteil Patienten von vornherein identifizieren zu können, die auf eine Immuntherapie ansprechen. Dadurch könnte den Patienten die nicht ansprechen von vornherein eine oft recht nebenwirkungsreiche Therapie erspart werden." }, "begin_planned": "2009-05-01T02:00:00+02:00", "begin_effective": "2009-05-01T02:00:00+02:00", "end_planned": "2009-07-01T02:00:00+02:00", "end_effective": "2010-12-31T01:00:00+01:00", "assignment": "2009-09-22T13:07:22+02:00", "program": null, "subprogram": null, "organization": 14056, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 1719, "title": { "de": "GATiB II - Koordination", "en": "GATiB II - Coordination" }, "short": "GATIB_II_Koordination", "url": null, "abstract": { "de": "Biobanken für die biomedizinische Forschung sind Sammlungen von biologischem Material (Gewebe, Zellen, Blut, Körperflüssigkeiten, inklusive der daraus isolierten Biomoleküle) und den zugehörigen Daten über den Probendonor. Diese biologischen Materialien enthalten wertvolle Informationen über genetische und nicht-genetische Krankheitsursachen und über Faktoren, die den Krankheitsverlauf beeinflussen. Aufgrund dieser Relevanz sehen mehrere internationale Organisationen biologische Materialien als essentielle Rohmaterialien, um den Fortschritt in Biotechnologie und Gesundheitswesen voranzutreiben.\r\nGATiB basiert auf einem einzigartigen Pathologiearchiv an der Medizinischen Universität Graz und enthält über 3 Millionen Proben von 800.000 Patienten, die nahezu alle Krankheiten einer mitteleuropäischen Bevölkerung in der natürlichen Häufigkeit abbilden.\r\n\r\nGEN-AU I förderte die Umwandlung dieses Archivs in eine Biobank (GATiB)\r\nSchwerpunkt in GEN-AU II war die Erhöhung des wissenschaftlichen Wertes und des Nutzens der 3 Millionen archivierter Proben durch halbautomatische Annotation der Proben mit medizinischen Daten und Patienten-Überlebensdaten.\r\nIn GEN-AU III wird GATiB II den Schwerpunkt auf die prospektive Sammlung von Proben und Daten, sowie internationale Integration legen. Es ist eine Probensammlung geplant, deren Design spezifisch die Forschung an metabolischen Erkrankungen unterstützt - eine anerkannte Stärke der Forschung an der Medizinischen Universität und den anderen Grazer Universitäten. Dies erfordert die Entwicklung verbesserter Gefrierkonservierungs- und Gefrierlagermethoden für Gewebe um das Potenzial moderner metabolomischer Analysemethoden optimal ausnützen zu können.", "en": "Biobanken für die biomedizinische Forschung sind Sammlungen von biologischem Material (Gewebe, Zellen, Blut, Körperflüssigkeiten, inklusive der daraus isolierten Biomoleküle) und den zugehörigen Daten über den Probendonor. Diese biologischen Materialien enthalten wertvolle Informationen über genetische und nicht-genetische Krankheitsursachen und über Faktoren, die den Krankheitsverlauf beeinflussen. Aufgrund dieser Relevanz sehen mehrere internationale Organisationen biologische Materialien als essentielle Rohmaterialien, um den Fortschritt in Biotechnologie und Gesundheitswesen voranzutreiben.\r\nGATiB basiert auf einem einzigartigen Pathologiearchiv an der Medizinischen Universität Graz und enthält über 3 Millionen Proben von 800.000 Patienten, die nahezu alle Krankheiten einer mitteleuropäischen Bevölkerung in der natürlichen Häufigkeit abbilden.\r\n\r\nGEN-AU I förderte die Umwandlung dieses Archivs in eine Biobank (GATiB)\r\nSchwerpunkt in GEN-AU II war die Erhöhung des wissenschaftlichen Wertes und des Nutzens der 3 Millionen archivierter Proben durch halbautomatische Annotation der Proben mit medizinischen Daten und Patienten-Überlebensdaten.\r\nIn GEN-AU III wird GATiB II den Schwerpunkt auf die prospektive Sammlung von Proben und Daten, sowie internationale Integration legen. Es ist eine Probensammlung geplant, deren Design spezifisch die Forschung an metabolischen Erkrankungen unterstützt - eine anerkannte Stärke der Forschung an der Medizinischen Universität und den anderen Grazer Universitäten. Dies erfordert die Entwicklung verbesserter Gefrierkonservierungs- und Gefrierlagermethoden für Gewebe um das Potenzial moderner metabolomischer Analysemethoden optimal ausnützen zu können." }, "begin_planned": "2009-05-01T02:00:00+02:00", "begin_effective": "2009-10-01T02:00:00+02:00", "end_planned": "2012-04-30T02:00:00+02:00", "end_effective": "2012-09-30T02:00:00+02:00", "assignment": "2009-01-15T10:26:42+01:00", "program": 73, "subprogram": null, "organization": 14020, "category": 10, "type": 10, "partner_function": 3, "manager": 51663, "contact": 51663, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 152 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1719-50828-12", "1719-51663-10" ] }, { "id": 1882, "title": { "de": "Analysis of drug-metabolizing enzyme polymorphisms for response to anthracycline-based neoadjuvant chemotherapy in breast cancer", "en": "Analysis of drug-metabolizing enzyme polymorphisms for response to anthracycline-based neoadjuvant chemotherapy in breast cancer" }, "short": "CHEMOTHERAP_BREAST CANCER", "url": null, "abstract": { "de": "Breast cancer is the most common malignancy affecting women. It is the second leading cause of cancer-related death in Europe and the United States. Despite several improvements in early diagnosis, surgical techniques and hormone-, immune- and chemotherapy, this disease remains a threat to life for a large number of women. Moreover, providing individual treatment with low toxicity but maximum benefit is still an unsolved problem.\r\nNeoadjuvant chemotherapy using anthracycline-containing regimes is a standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. The main goal of neoadjuvant chemotherapy is to eliminate potential micrometastasis, thus improving disease-free survial.\r\nPharmacogenetics is aimed at understanding and predicting an individual's drug response based upon genetic variation.\r\n\r\nIn this pharmacogenetic project we investigate a set of heritable genetic factors in drug-metabolizing enzymes that might predict drug-induced anti-tumor response and toxicity of anthracycline-based neoadjuvant therapy in breast cancer, based upon multigenetic analysis.", "en": "Breast cancer is the most common malignancy affecting women. It is the second leading cause of cancer-related death in Europe and the United States. Despite several improvements in early diagnosis, surgical techniques and hormone-, immune- and chemotherapy, this disease remains a threat to life for a large number of women. Moreover, providing individual treatment with low toxicity but maximum benefit is still an unsolved problem.\r\nNeoadjuvant chemotherapy using anthracycline-containing regimes is a standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. The main goal of neoadjuvant chemotherapy is to eliminate potential micrometastasis, thus improving disease-free survial.\r\nPharmacogenetics is aimed at understanding and predicting an individual's drug response based upon genetic variation.\r\n\r\nIn this pharmacogenetic project we investigate a set of heritable genetic factors in drug-metabolizing enzymes that might predict drug-induced anti-tumor response and toxicity of anthracycline-based neoadjuvant therapy in breast cancer, based upon multigenetic analysis." }, "begin_planned": "2009-05-01T02:00:00+02:00", "begin_effective": "2009-05-01T02:00:00+02:00", "end_planned": "2009-09-30T02:00:00+02:00", "end_effective": "2010-09-30T02:00:00+02:00", "assignment": "2009-08-03T14:52:33+02:00", "program": null, "subprogram": null, "organization": 14085, "category": 10, "type": 10, "partner_function": 4, "manager": 58814, "contact": 58814, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 457 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1882-58814-10" ] }, { "id": 1908, "title": { "de": "GATiB II - Subprojekt 1", "en": "GATiB II - Subproject 1" }, "short": "GATiB II - Subprojekt 1", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-05-01T02:00:00+02:00", "begin_effective": "2009-10-01T02:00:00+02:00", "end_planned": "2012-04-30T02:00:00+02:00", "end_effective": "2012-09-30T02:00:00+02:00", "assignment": "2009-09-03T17:01:48+02:00", "program": 73, "subprogram": null, "organization": 14020, "category": 10, "type": 10, "partner_function": 2, "manager": 51663, "contact": 51663, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 152 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1908-51663-10" ] }, { "id": 2151, "title": { "de": "Entwicklung eines praktikablen Werkzeugs für die Bewertung und Implementierung evidenzbasierter Leitlinien in Kooperation mit den Krankenhäusern in der Steiermark", "en": "Entwicklung eines praktikablen Werkzeugs für die Bewertung und Implementierung evidenzbasierter Leitlinien in Kooperation mit den Krankenhäusern in der Steiermark" }, "short": "EVIDENZBASIERTE LEITLINIEN", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-05-01T02:00:00+02:00", "begin_effective": "2009-05-01T02:00:00+02:00", "end_planned": "2011-04-30T02:00:00+02:00", "end_effective": "2011-04-30T02:00:00+02:00", "assignment": "2010-03-04T12:31:15+01:00", "program": null, "subprogram": null, "organization": 14026, "category": 10, "type": 10, "partner_function": 4, "manager": 51098, "contact": 51098, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2151-51098-10" ] }, { "id": 1777, "title": { "de": "The role of C/EBPa on the development of monocyte subsets", "en": "The role of C/EBPa on the development of monocyte subsets" }, "short": "C/EBPa", "url": null, "abstract": { "de": "The integrity of the hematopoietic system depends on a large number of blood cell lineages being continuously replenished from a rare population of pluripotent heatopoietic stem cells(HSC), representing a paradigm for how multilineage diversity can be achieved from a common stem cell through lineage commitment and subsequent differentiation.\r\nMonocytes are mononuclear cells and represent about 10% of leukocytes in human blood and 4% of leukocytes in mouse blood. The best known function of monocytes is their role as accessory cells, which link inflammation and the innate defense system against microorganisms to adaptive immune response.\r\nMany factors are involved in monocyte differentiation like PU.1, IRF8, KLF-4, MafB, c-maf and C/EBPalpha. C/EBPalpha (CCAAT/enhancer binding protein alpha) is a basic region-leucine zipper transcription factor and indispensable for formation of mature neutrophils and eosinophils. It is expressed at low levels in HSC, and is up-regulated to its highest levels in GMP(granulocyte/monocyte progenitors), whereas it is not expressed in precursors of lymphoid cells and is downregulated as CMP differentiate to MEP(megakaryocyte/erythrocyte progenitors). Mice-studies indicate that C/EBPalpha is essential for transition of CMP to GMP.\r\n\r\nWe hypothesize that C/EBPalpha positive and C/EBPalpha negative monocytes represent distinct subgroups of monocytes, which also differ in their function. In addition, we speculate that they are derived from different progenitors. To experimentally approach this hypothesis we want to use the C/EBPalphaCRE EYFP reporter mouse model.", "en": "The integrity of the hematopoietic system depends on a large number of blood cell lineages being continuously replenished from a rare population of pluripotent heatopoietic stem cells(HSC), representing a paradigm for how multilineage diversity can be achieved from a common stem cell through lineage commitment and subsequent differentiation.\r\nMonocytes are mononuclear cells and represent about 10% of leukocytes in human blood and 4% of leukocytes in mouse blood. The best known function of monocytes is their role as accessory cells, which link inflammation and the innate defense system against microorganisms to adaptive immune response.\r\nMany factors are involved in monocyte differentiation like PU.1, IRF8, KLF-4, MafB, c-maf and C/EBPalpha. C/EBPalpha (CCAAT/enhancer binding protein alpha) is a basic region-leucine zipper transcription factor and indispensable for formation of mature neutrophils and eosinophils. It is expressed at low levels in HSC, and is up-regulated to its highest levels in GMP(granulocyte/monocyte progenitors), whereas it is not expressed in precursors of lymphoid cells and is downregulated as CMP differentiate to MEP(megakaryocyte/erythrocyte progenitors). Mice-studies indicate that C/EBPalpha is essential for transition of CMP to GMP.\r\n\r\nWe hypothesize that C/EBPalpha positive and C/EBPalpha negative monocytes represent distinct subgroups of monocytes, which also differ in their function. In addition, we speculate that they are derived from different progenitors. To experimentally approach this hypothesis we want to use the C/EBPalphaCRE EYFP reporter mouse model." }, "begin_planned": "2009-05-01T02:00:00+02:00", "begin_effective": "2009-08-01T02:00:00+02:00", "end_planned": "2010-04-30T02:00:00+02:00", "end_effective": "2013-07-31T02:00:00+02:00", "assignment": "2009-04-07T10:52:48+02:00", "program": null, "subprogram": null, "organization": 14082, "category": 10, "type": 10, "partner_function": 4, "manager": 51911, "contact": 51911, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 423 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1777-58889-12", "1777-51911-10" ] }, { "id": 1720, "title": { "de": "GATIB II, Genome Austria Tissue Bank (GEN-AU III)", "en": "GATIB II, Genome Austria Tissue Bank (GEN-AU III)" }, "short": "GATIB II_GENAU_III_Trauner", "url": null, "abstract": { "de": "Biobanken für die biomedizinische Forschung sind Sammlungen von biologischem Material (Gewebe, Zellen, Blut, Körperflüssigkeiten, inklusive der daraus isolierten Biomoleküle) und den zugehörigen Daten über den Probendonor. Diese biologischen Materialien enthalten wertvolle Informationen über genetische und nicht-genetische Krankheitsursachen und über Faktoren, die den Krankheitsverlauf beeinflussen. Aufgrund dieser Relevanz sehen mehrere internationale Organisationen biologische Materialien als essentielle Rohmaterialien, um den Fortschritt in Biotechnologie und Gesundheitswesen voranzutreiben.\r\nGATiB basiert auf einem einzigartigen Pathologiearchiv an der Medizinischen Universität Graz und enthält über 3 Millionen Proben von 800.000 Patienten, die nahezu alle Krankheiten einer mitteleuropäischen Bevölkerung in der natürlichen Häufigkeit abbilden.\r\n\r\nGEN-AU I förderte die Umwandlung dieses Archivs in eine Biobank (GATiB)\r\nSchwerpunkt in GEN-AU II war die Erhöhung des wissenschaftlichen Wertes und des Nutzens der 3 Millionen archivierter Proben durch halbautomatische Annotation der Proben mit medizinischen Daten und Patienten-Überlebensdaten.\r\nIn GEN-AU III wird GATiB II den Schwerpunkt auf die prospektive Sammlung von Proben und Daten, sowie internationale Integration legen. Es ist eine Probensammlung geplant, deren Design spezifisch die Forschung an metabolischen Erkrankungen unterstützt - eine anerkannte Stärke der Forschung an der Medizinischen Universität und den anderen Grazer Universitäten. Dies erfordert die Entwicklung verbesserter Gefrierkonservierungs- und Gefrierlagermethoden für Gewebe um das Potenzial moderner metabolomischer Analysemethoden optimal ausnützen zu können.", "en": "Biobanken für die biomedizinische Forschung sind Sammlungen von biologischem Material (Gewebe, Zellen, Blut, Körperflüssigkeiten, inklusive der daraus isolierten Biomoleküle) und den zugehörigen Daten über den Probendonor. Diese biologischen Materialien enthalten wertvolle Informationen über genetische und nicht-genetische Krankheitsursachen und über Faktoren, die den Krankheitsverlauf beeinflussen. Aufgrund dieser Relevanz sehen mehrere internationale Organisationen biologische Materialien als essentielle Rohmaterialien, um den Fortschritt in Biotechnologie und Gesundheitswesen voranzutreiben.\r\nGATiB basiert auf einem einzigartigen Pathologiearchiv an der Medizinischen Universität Graz und enthält über 3 Millionen Proben von 800.000 Patienten, die nahezu alle Krankheiten einer mitteleuropäischen Bevölkerung in der natürlichen Häufigkeit abbilden.\r\n\r\nGEN-AU I förderte die Umwandlung dieses Archivs in eine Biobank (GATiB)\r\nSchwerpunkt in GEN-AU II war die Erhöhung des wissenschaftlichen Wertes und des Nutzens der 3 Millionen archivierter Proben durch halbautomatische Annotation der Proben mit medizinischen Daten und Patienten-Überlebensdaten.\r\nIn GEN-AU III wird GATiB II den Schwerpunkt auf die prospektive Sammlung von Proben und Daten, sowie internationale Integration legen. Es ist eine Probensammlung geplant, deren Design spezifisch die Forschung an metabolischen Erkrankungen unterstützt - eine anerkannte Stärke der Forschung an der Medizinischen Universität und den anderen Grazer Universitäten. Dies erfordert die Entwicklung verbesserter Gefrierkonservierungs- und Gefrierlagermethoden für Gewebe um das Potenzial moderner metabolomischer Analysemethoden optimal ausnützen zu können." }, "begin_planned": "2009-05-01T02:00:00+02:00", "begin_effective": "2009-10-01T02:00:00+02:00", "end_planned": "2012-04-30T02:00:00+02:00", "end_effective": "2012-06-30T02:00:00+02:00", "assignment": "2009-01-15T10:32:33+01:00", "program": 73, "subprogram": null, "organization": 14081, "category": 10, "type": 10, "partner_function": 2, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 152 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 2398, "title": { "de": "SIMNET STYRIA 2009/2010", "en": "SIMNET STYRIA 2009/2010" }, "short": "SIMNET", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-05-18T02:00:00+02:00", "begin_effective": "2009-05-18T02:00:00+02:00", "end_planned": "2011-05-31T02:00:00+02:00", "end_effective": "2011-05-31T02:00:00+02:00", "assignment": "2011-02-07T14:48:55+01:00", "program": null, "subprogram": null, "organization": 14011, "category": 10, "type": 10, "partner_function": 2, "manager": 50966, "contact": 50966, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2398-50966-10" ] } ] }